We are seeking start-ups or researchers focused on new sensing approaches relevant to industrial/manufacturing processes to participate in the Anglo American FutureSmart MiningTM Sensing Open Forum taking place virtually from June 9th - 17th 2021.
The chemical industry is increasingly leveraging artificial Intelligence in their quest for new synthetic routes and chemical structures used in a wide variety of applications including: building materials, packaging, agrochemicals, pharmaceuticals, and consumer products. While past efforts focused on optimizing time and cost of producing materials, growing environmental concerns, and new legislation lead manufacturers to address the environmental impact and sustainability of their products. In this webinar we present research on, and application of, computer-assisted technologies to assist researchers and corporate R&D scientists and engineers in identifying and leveraging environmentally friendly chemistry and materials.
Looking for 8-10 startups to present their tech on April 12 at the 2022 MIT Health Science Technologies Conference: The Future of Cell & Gene Therapies.
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.
Evonik's Open Challenge is an opportunity for innovative partners to develop new adhesives that can debond and explore applications for on-demand debonding.
THK is seeking a development partner to create a stable wireless environment for their customers.
Anglo American, a British mining company, is looking for startups in bio technology, rapid access, improved recovery, dry processing, mining legacy, sensor fusion, and EPC disruption.
Murata is seeking startups to trial its innovative cell fractionation filter, CELLNETTA, to identify key challenges this product can solve.
Japanese multinational company looking globally for startups to collaborate with in the field of energy storage and related battery systems.